A Blowout Call on Biotech Select

I have two simple goals with this brief missive: Give well-deserved kudos to Adam Feuerstein for his call on CV Therapeutics ( CVTX) that he recently added to the portfolio of Biotech Select, a premium service from TheStreet.com. And second, if you're interested in biotech stocks, you should subscribe to Biotech Select.

Adam added CV Therapeutics to the model portfolio of Biotech Select on Jan. 20, when the stock was trading at $10.75 a share. Shares of CVTX rose to $16.68 in intraday trading today on news that the company had received and rejected a $16-per-share takeover offer from Japanese drugmaker Astellas.

Subscribers of Biotech Select who followed Feuerstein's buy suggestion gained more than 50% from this position in just five trading days!

Nice work, Adam. Click here to take a free trial to Biotech Select and receive all of Adam's commentary and stock recommendations.

Let's stay interactive.

Dave Morrow

Editor-in-Chief

David Morrow is editor-in-chief of TheStreet.com. In keeping with TSC's editorial policy, he doesn't own or short individual stocks, though he owns stock in TheStreet.com. He also doesn't invest in hedge funds or other private investment partnerships. He appreciates your feedback; click here to send him an email.

More from Personal Finance

All 2018 Graduates Must Watch Jim Cramer's Bucknell Commencement Speech

All 2018 Graduates Must Watch Jim Cramer's Bucknell Commencement Speech

The Best Investment Advice? Stay Diversified

The Best Investment Advice? Stay Diversified

Use This Simple Investing Strategy to Stay Ahead in a Rollercoaster Stock Market

Use This Simple Investing Strategy to Stay Ahead in a Rollercoaster Stock Market

5 Most Ridiculous Royal Wedding Memorabilia Items

5 Most Ridiculous Royal Wedding Memorabilia Items

7 Ways Your Financial Adviser Should Help You Survive Rising Interest Rates

7 Ways Your Financial Adviser Should Help You Survive Rising Interest Rates